Do Traders Think Aurinia Pharmaceuticals Inc (AUPH) Can Turn Around Friday?

Overall market sentiment has been down on Aurinia Pharmaceuticals Inc (AUPH) stock lately. AUPH receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

Aurinia Pharmaceuticals Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on AUPH!

See Full AUPH Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With AUPH Stock Today?

Aurinia Pharmaceuticals Inc (AUPH) stock is trading at $8.39 as of 1:28 PM on Friday, Jan 20, an increase of $0.46, or 5.8% from the previous closing price of $7.93. The stock has traded between $7.86 and $8.58 so far today. Volume today is light. So far 1,593,801 shares have traded compared to average volume of 3,359,729 shares.

More About Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States. Click Here to get the full Stock Report for Aurinia Pharmaceuticals Inc stock.